NCT03738241: A reported trial by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03738241 |
|---|---|
| Title | A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 18, 2018 |
| Completion date | June 19, 2020 |
| Required reporting date | June 19, 2021, midnight |
| Actual reporting date | June 10, 2021 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |